ClinicalTrials.gg
CompletedNCT00643643Updated Nov 10, 2010

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

A Phase 2 interventional study of Maraviroc (UK-427,857) and Maraviroc (UK-427,857) in HIV Infections, sponsored by ViiV Healthcare. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-11-10.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.

Enrollment
20th of 44
41 · median 36
Started
2002
the only one that year
Phase 2
7 of 44
none open now
Registered
8th of 44
by date
Lead sponsor
8 of 44
ViiV Healthcare

Among the 44 studies testing maraviroc in HIV Infections, this one is the 20th largest by enrollment, is the only one that started in 2002, is one of 7 in phase 2, and was the 8th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing maraviroc in HIV Infections as a file.
02

Study summary

To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Treatment Naïve
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria:

  • Male with or surgically sterilized female with HIV showing no symptoms of HIV
  • Weight between 50 and 90kg and within the permitted range for their height

Exclusion Criteria:

Exclusion criteria:

  • Subjects with a less than 250cells/mm3 or HIV viral load of less than 5000 copies/mL
  • Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis
  • Subjects whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion
  • Subjects who have taken anti-retroviral drugs in the eight weeks prior to the study screening visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    A

    Drug: Maraviroc (UK-427,857)

  • Experimental
    B

    Drug: Maraviroc (UK-427,857)

  • Experimental
    C

    Drug: Maraviroc (UK-427,857)

  • Experimental
    D

    Drug: Maraviroc (UK-427,857)

  • Placebo comparator
    E

    Other: Placebo

Interventions

  • 25 mg oral tablet once daily for 10 days

    Also known as: Celsentri, Selzentry

  • 50 mg oral tablet twice daily for 10 days

    Also known as: Celsentri, Selzentry

  • 100 mg oral tablet twice daily for 10 days

    Also known as: Celsentri, Selzentry

  • 300 mg oral tablet twice daily for 10 days

    Also known as: Celsentri, Selzentry

  • OtherPlacebo

    Matching placebo oral tablet twice daily for 10 days

    Also known as: Celsentri, Selzentry

06

What researchers measure

Primary outcomes

  1. Change from baseline in viral load

    Time frame: Day 11

  2. Pharmacokinetic profile of UK-427,857

    Time frame: Days 1 and 10

  3. Receptor saturation

    Time frame: Days 1, 5, 10, 11, 13, 15, 19, 40

Secondary outcomes

  1. 12-lead electrocardiography

    Time frame: Days 1-11 and Day 40

  2. Time course of viral load from baseline to follow-up

    Time frame: Days 1-15 and Days 19, 22, 25, 40

  3. Time to rebound of viral load

    Time frame: Days 1-15 and Days 19, 22, 25, 40

  4. The relationship of change in viral load (from baseline to day 11) versus average (Days 1-11) and trough (Day 10) plasma concentrations

    Time frame: Days 1-11

  5. The relationship of change in viral load (from baseline to day 11) versus mean receptor saturation (Day 10)

    Time frame: Days 1-11

  6. The relationship of change from baseline in viral load versus baseline virus susceptibility (IC 50 and IC 90)

    Time frame: Days 1-11

  7. Adverse events

    Time frame: Days 1-40

  8. Laboratory safety testing

    Time frame: Days 1, 3, 7, 11, 15, 40

  9. Physical examination

    Time frame: Days 1, 11, 40

  10. Supine and standing blood pressure and pulse rate

    Time frame: Days 1-11 and Day 40

07

Study locations

6 sites
  • Pfizer Investigational Site
    Bonn, 53105, Germany
  • Pfizer Investigational Site
    Koeln, 50924, Germany
  • Pfizer Investigational Site
    Muenchen, 80336, Germany
  • Pfizer Investigational Site
    Utrecht, 3584 CX, Netherlands
  • Pfizer Investigational Site
    London, NW3 2QG, United Kingdom
  • Pfizer Investigational Site
    London, SW10 9NH, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 26, 2008
Start
Oct 2002
Primary completionActual
Jun 2003
CompletionActual
Jun 2003
Last update
Nov 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00643643
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
First posted
Mar 26, 2008
Start date
Oct 2002
Primary completion
Jun 2003
Completion
Jun 2003
Last update
Nov 10, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion